Remodeling the Host Immune Microenvironment in Carbapenem-Resistant Klebsiella pneumoniae: An Evidence-Graded Framework for Host-Directed Intervention
Klebsiella pneumoniae occupies the top tier of the WHO priority pathogen list. The simultaneous emergence of carbapenem resistance and hypervirulence undermines pathogen-directed therapies because carbapenemases render many antibiotics ineffective. As an alternative, host-directed therapy (HDT) targets host pathways and immune responses, making these approaches largely indifferent to bacterial carbapenemases. The reviewed work frames HDT as a structural alternative to antimicrobials for difficult-to-treat K. pneumoniae infections, particularly where resistance compromises standard therapy.
The pathogen reshapes the host immune microenvironment through four principal mechanisms that contribute to persistence and pathogenesis:
Suppression of NF-κB/MAPK/interferon signaling, dampening proinflammatory transcriptional responses that would normally coordinate pathogen clearance.
Blunting of inflammasome activation and oxidative-burst effectors, reducing mechanisms that generate microbicidal reactive oxygen species and inflammatory cytokines.
Reprogramming of macrophages into an intracellular M(Kp) sanctuary, whereby macrophage polarization and intracellular niches favor bacterial survival rather than clearance.
Depletion of the lymphocyte compartment, weakening adaptive immune surveillance and effector functions.
These mechanisms are characterized in the literature and provide discrete evasion nodes suitable for therapeutic targeting.
The authors map each identified evasion node onto candidate pharmacological agents and natural products, and they grade these options by the directness of supporting evidence. The grading reflects whether interventions were tested in carbapenem-resistant or multidrug-resistant (MDR) K. pneumoniae isolates specifically, validated in K. pneumoniae more generally, or extrapolated from related fields such as sepsis or oncology. The review emphasizes that most claims do not yet reach the level of direct evidence in resistant isolates and that the resulting map is hypothesis-generating rather than a validated treatment algorithm.
Four strategies were identified as carrying direct evidence in carbapenem-resistant or MDR K. pneumoniae contexts:
Recombinant IL-22 — identified as a host cytokine-based intervention with direct supportive evidence in resistant or MDR isolates.
L-arginine supplementation — proposed as a metabolic support or immunomodulatory intervention with direct evidence in resistant contexts.
Autophagy-inducing sensitization — interventions that promote autophagy to enhance intracellular bacterial clearance have direct evidence in resistant or MDR settings.
T-cell correction strategies — approaches to restore or correct T-cell function are supported by direct evidence in resistant or MDR K. pneumoniae.
The review notes these four as the most directly evidenced HDT candidates in the specific setting of resistant isolates.
Two practical principles inform how HDT should be deployed:
Resistance-agnostic efficacy: Because HDT acts on host targets, therapeutic effects are largely independent of bacterial carbapenemases and other resistance mechanisms.
Directional, phase-dependent hazard: Immune modulators may be beneficial in certain disease phases or tissue compartments but harmful in others. Timing, patient state, and immunologic compartmentalization therefore determine whether a given intervention helps or harms.
These principles argue for careful clinical stratification and context-sensitive use of HDT.
The review highlights several caveats that constrain straightforward translation of candidate HDTs:
Hypervirulent CRKP strains can repress autophagy, potentially reversing benefits observed with autophagy agonists validated only in non-hypervirulent isolates.
Many natural products tend to favor M2 macrophage polarization; while M2 polarization can be anti-inflammatory, it may also reinforce bacterial persistence within macrophage sanctuaries.
Antibiotics can antagonize microbiota-restoring interventions, implying that microbiome-directed HDT may require sequential rather than concurrent use with antimicrobials.
Taken together, these caveats underscore that HDT effects are context-dependent and may vary with strain virulence, host phase, and concurrent therapies.
Several individual biomarkers already show preliminary clinical stratification value in contexts relevant to CRKP infection and immunoparalysis:
mHLA-DR and the neutrophil-to-lymphocyte ratio have validated thresholds for detecting immunoparalysis in clinical settings.
An inverted CD4/CD8 ratio has been documented in cohorts with CRKP.
What is not yet validated is the integration of these and other markers into a continuous, multi-marker "intervention-window" score that would guide timing and selection of HDT. The authors indicate that such integration remains an unvalidated but promising direction.
Most mapped interventions and natural products lack direct evidence in carbapenem-resistant isolates; only four therapeutic nodes currently meet that criterion. The authors convert the remaining evidence gaps into a structured research agenda aimed at prioritizing validation studies, clarifying phase- and compartment-specific effects, and developing integrated biomarker-driven scores for clinical stratification. They emphasize that the present framework is hypothesis-generating and intended to direct future preclinical and clinical research rather than serve as a validated clinical algorithm.
(Conflict of interest: the authors declared no competing interests.)